Skip to main content

Clinical trial TG6002.02

A Phase I/IIa study of TG6002 (VV TK-RR-FCU1) administered by intravenous (IV) infusions in combination with oral flucytosine (5-FC) in patients with advanced gastro-intestinal (GI) tumors

Cancers
Organ gastric
Trial status Trial open for recruitment
Investigator
Trial type
Prospective interventional
Phase Trial phase 1
Academic trial Non
Sponsor Transgene S.A.
EudraCT Identifier 2018-000039-28
Inclusion criteria After standard therapy / RECIST 1.1
Last update

Follow us!

Support research

Support research

Research at the Institut Jules Bordet depends on your generosity. Make a donation today and join us in the fight against cancer.

Learn more